Helen Fisher

Non-Executive Director / Paradigm Biopharmaceuticals

Helen Fisher is the chief executive and managing director of Bio Capital Impact Fund and a director of NovellusDx, a personalised cancer diagnostics company.

Prior to establishing the Bio Capital Impact Fund in 2017, Ms Fisher was a partner of Deloitte and led its life sciences industry practice in Australia for 5 years.

She has provided strategic tax advice to public-listed and large multinational companies and has extensive experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP management and location, and supply chain management.

Lists and Charts

Roles

2020

Non-Executive Director

Calix

Year started and most recent title

Total Shareholder Return as at 02/12/24

Rank	Company	1 Yr	5 Yr
1751^st	Future Battery Minerals	-74.32%	-24.21%
1752^nd	Intra Energy Corporation	-74.43%	-29.74%
1753^rd	Calix	-74.86%	2.38%
1754^th	Riedel Resources	-74.93%	-35.04%
1755^th	Krakatoa Resources	-74.97%	-23.47%

View Full List

1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

Person Activity

	NEW ROLE: Non-Executive Director, Paradigm Biopharmaceuticals	13 Apr 2022
	NEW ROLE: Non-Executive Director, Calix	03 Nov 2020
	NEW ROLE: Partner, Tax, Deloitte	03 Aug 2020
	NEW ROLE: Non-Executive Director, Sienna Cancer Diagnostics	03 Aug 2020
	NEW ROLE: Non-Executive Director, INOVIQ	03 Aug 2020

Article Timeline

Related Information

Access to our data for Helen Fisher is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Helen Fisher is linked to 5 organisations which are included in 1 list - Public Companies - non WA.

To see the data you will need to Subscribe.